190 related articles for article (PubMed ID: 25888530)
1. A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40.
Chen J; Zurawski G; Zurawski S; Wang Z; Akagawa K; Oh S; Hideki U; Fay J; Banchereau J; Song W; Palucka AK
J Hematol Oncol; 2015 Apr; 8():35. PubMed ID: 25888530
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy.
Wang M; Sun L; Qian J; Han X; Zhang L; Lin P; Cai Z; Yi Q
Leukemia; 2009 Jul; 23(7):1320-8. PubMed ID: 19225534
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model.
Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT
Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
Guidoboni M; Zancai P; Cariati R; Rizzo S; Dal Col J; Pavan A; Gloghini A; Spina M; Cuneo A; Pomponi F; Bononi A; Doglioni C; Maestro R; Carbone A; Boiocchi M; Dolcetti R
Cancer Res; 2005 Jan; 65(2):587-95. PubMed ID: 15695403
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy.
Kondo E; Maecker B; Weihrauch MR; Wickenhauser C; Zeng W; Nadler LM; Schultze JL; von Bergwelt-Baildon MS
Clin Cancer Res; 2008 Oct; 14(20):6574-9. PubMed ID: 18927298
[TBL] [Abstract][Full Text] [Related]
7. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells.
Kim YS; Kim YJ; Lee JM; Han SH; Ko HJ; Park HJ; Pereboev A; Nguyen HH; Kang CY
Hum Gene Ther; 2010 Dec; 21(12):1697-706. PubMed ID: 20604681
[TBL] [Abstract][Full Text] [Related]
8. Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice.
Justesen S; Buus S; Claesson MH; Pedersen AE
Immunology; 2007 Nov; 122(3):326-34. PubMed ID: 17610503
[TBL] [Abstract][Full Text] [Related]
9. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based therapy for mantle cell lymphoma.
Munger CM; Vose JM; Joshi SS
Int J Oncol; 2006 Jun; 28(6):1337-43. PubMed ID: 16685434
[TBL] [Abstract][Full Text] [Related]
11. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
[TBL] [Abstract][Full Text] [Related]
12. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
13. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
[TBL] [Abstract][Full Text] [Related]
14. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
17. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.
Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD
Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119
[TBL] [Abstract][Full Text] [Related]
19. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas.
Thomázy VA; Luthra R; Uthman MO; Davies PJ; Medeiros LJ
J Mol Diagn; 2002 Nov; 4(4):201-8. PubMed ID: 12411587
[TBL] [Abstract][Full Text] [Related]
20. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]